Search Results for: FSD Pharma

FSD Pharma Announces Launch of IBS Clinical Study

CANADA: FSD Pharma has announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics. The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

The double-blind, randomized, placebo-controlled study will enroll 20 patients in a cross-over design to comply with the highest standards of rigorous scientific validity and certification demands of international medical regulatory authorities.

Under the terms of FSD’s strategic agreement with SciCann, the Company holds exclusive manufacturing and distribution rights for the “Steady Stomach” product in Canada.

The study’s principal investigator is Dr. Bryan Doner of Compassionate Care Certifications Centers in Pittsburgh, Pennsylvania and the CRO is Affinity Bio Partners, led by CEO Dr. Christina DiArcangelo Puller.

Dr. Raza Bokhari, CEO of FSD Pharma, stated, “This innovative clinical study aims to demonstrate the safety and efficacy of this easy-to-administer, side-effect-free therapy for a very common disease. Although rarely spoken about, IBS causes suffering to many patients around the world by dramatically reducing quality of life. The launch of this study marks another important milestone for FSD on its way to becoming a leading supplier of superior and differentiated medical, cannabis-based therapies for patients. Together with our partner SciCann, FSD is working tirelessly towards the development of novel and disruptive cannabinoid-based therapies for the world’s most under-treated diseases and irritable bowel syndrome is high on our list of target indications.”

Dr. Zohar Koren, co-founder and CEO of SciCann Therapeutics, stated, “The prevalence of irritable bowel syndrome is estimated at 10-15 percent of the global population. This is an under-diagnosed, hard-to-treat condition that causes an estimated cost to society of over US$21 billion annually in direct medical expenses and indirect costs associated with loss of productivity1. Based on our research, we believe that our proprietary “Steady Stomach” CBD combination product can serve as a new treatment standard to improve the lives of patients. We are looking forward to reporting on the results of this clinical study. ”

FSD Pharma Begins Construction Of Heritage Museum & Flagship Dispensary In Ontario

CANADA: FSD Pharma Inc. announced that construction has commenced of its heritage museum and flagship dispensary at the former Kraft plant in Cobourg, Ontario, headquarters of its wholly-owned subsidiary FV Pharma Inc.

Local politicians and media will be in attendance at the ribbon-cutting ceremony on October 9, 2018 at 11:30 EST in Cobourg at the Head office located at 520 William Street. Honoured invited guests include Cobourg Mayor Gil Brocanier who will be in attendance and the Hon. Kim Rudd, MP for Northumberland and Peterborough South who is expected to attend. All national media are welcome with media credentials.

Thomas Fairfull, President and CEO of FSD Pharma stated, “We welcome politicians and media to this momentous event where we begin converting the historic Certo building located at the former Kraft plant into a heritage museum and on-site dispensary. The Certo building is an important part of Cobourg’s history and the Company intends to preserve this unique building.”

The former Certo building was the first in the British Empire to make commercial grade pectin that was sold under the product name of “Certo” and is estimated at over 100 years old. The property is listed on the municipal heritage register as a property of cultural heritage value. Last year, Cobourg City Council endorsed several recommendations, including the designation of the Certo building under the Ontario Heritage Act as a building of cultural heritage value.

“Today, we also begin construction of our flagship on-site dispensary, an important component of our business plan as we sit on the brink of adult-use legalization on October 17, 2018. The Company is preparing in earnest for sales of our high quality, indoor grown and pharmaceutical grade product, which will be available for sale shortly,” continued Fairfull.

 

FSD Pharma Expands Into Jamaican Market

CANADA: FSD Pharma has announce that it intends to launch a strategic partnership into the Jamaican cannabis market as part of its plan to expand internationally. FSD has signed a Letter of Intent effective September 10, 2018 with JJAMACANN Inc. to form a joint venture operating as FSD Jamaica. FSD Jamaica expects to partner locally with Nature’s Purest Limited, a Jamaican corporation with a cultivation license and existing operations in Jamaica.

“We are excited to be working with a world-class and knowledgeable team of local experts and entrepreneurs with extensive cannabis cultivation experience. Jamaica has historically produced some of the best cannabis over the past 50 years. FSD Jamaica intends to take advantage of the ideal climate and soil conditions on the NPL property and surrounding area to produce the highest quality cannabis, hemp and cannabinoid products possible. FSD Jamaica is well-positioned to bring Jamaican branded, world class medical and recreational products to market by 2019”, said Anthony Durkacz, Director of FSD.

As part of the LOI, FSD Jamaica will establish an experimental centre for the development of cannabis and cannabinoid (CBD) genetics suitable to cultivate in Jamaica with the intent to create a genetics and seed bank of innovative cannabis and hemp products for the Jamaican market and the Canadian market where permitted.

“NPL was the second company to be granted a cultivation license in Jamaica. It is located in the beautiful mountains of Ulster Springs Trelawny and the property is fed by crystal clear spring water surrounded by many agricultural crops and experienced workers. The combined genetics library of FSD Jamaica and NPL will allow for the breeding of high THC & CBD plants that will be cultivated using medical grade extraction processes. This strategic partnership compliments FSD’s business model of producing the highest quality medical grade product at scale”, continued Mr. Durkacz.

FSD Pharma Inks Saskatchewan Wholesale Supply MOU With High Tide Ventures

CANADA: FSD Pharma this week announced that its wholly-owned subsidiary, FV Pharma Inc. has entered into a non-binding memorandum of understanding with High Tide Ventures Inc. (“High Tide”) dated July 18, 2018 to supply the Saskatchewan market on a wholesale basis with up to 5,000 kilograms of cannabis products over the next year when available. FSD Pharma is working together with Auxly (formerly Cannabis Wheaton Income Corp.) to achieve its mission to develop the largest hydroponic indoor cannabis cultivation facility in Cobourg, Ontario, Canada.

FSD PHARMA ENTERS INTO SASKATCHEWAN WHOLESALE SUPPLY MOU OF UP TO 5,000 KILOGRAMS WITH HIGH TIDE VENTURES

FSD PHARMA ENTERS INTO SASKATCHEWAN WHOLESALE SUPPLY MOU OF UP TO 5,000 KILOGRAMS WITH HIGH TIDE VENTURES

High Tide is in the process of becoming a licensed wholesaler of cannabis products in the province of Saskatchewan. Thomas Fairfull, President and CEO of FSD Pharma, stated, “This non-binding MOU is the result of FSD Pharma’s focus on growing high quality indoor hydroponic cannabis, which I expect will yield more opportunities to build on our relationship in the near future.” Raj Grover, President & Chief Executive Officer of High Tide, added, “High Tide has achieved an important strategic milestone by securing its first wholesale business partner for Saskatchewan and the province’s 51 retail cannabis outlets. It is very important to us to be able to provide the highest quality of indoor grown cannabis. We want to ensure that High Tide is able to offer consumers a variety of options that they actually enjoy.”

High Tide is focused on becoming a strong downstream player in the legal recreational cannabis industry in Canada. Through its subsidiaries, High Tide has also applied for over 30 retail cannabis licenses and associated development permits in Alberta, with applications in British Columbia expected to be submitted shortly.

 

FSD Pharma Announces Acquisition To Expand In Newfoundland

CANADA: FSD Pharma announced a binding agreement to purchase 51% of Atlantic Island Cannabis (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018.

The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland. In the first phase of the project, an indoor high quality 45,000 square foot cannabis production facility will be set up in Freshwater, Carbonear, Newfoundland. This site is expected to bring about economic benefits for the province and to create 200 local, management and construction jobs through a phased expansion approach. Phase two of the project will involve a further expansion of the indoor grow facility to up to approximately 300,000 square feet for the production and processing of legal cannabis.

The purchase price for 51% of Atlantic Island Cannabis Inc. is $6,500,000 payable in Class B subordinated shares of FSD based on a 15 day Volume Weighted Average Price. The site will initially be leased but FSD has the option to purchase the site at any time for $1,500,000. The FSD shares issued will be escrowed subject to completion of a number of conditions, including but not limited to, due diligence by FSD, satisfactory documentation, receipt of third party consents and a valid purchase order from the government of Newfoundland.

The closing date is expected to occur on or before August 31, 2018.

“Newfoundland is a fantastic province with outstanding, highly skilled people,” said Thomas Fairfull, President and CEO, FSD Pharma Inc. “This is another expansion milestone for FSD Pharma as we continue to grow our production and distribution footprint nationally.”

Speaking about the agreement, Suman Pushparajah, Chairman, Atlantic Pharma Inc. said: “One of the compelling factors for us in considering this association is the scope of benefits for the local population. We have outlined a phased growth plan to set up a long term sustainable business model for the community of Freshwater, Carbonear, Newfoundland. Seeing a real value in partnering with FSD Pharma, we are approaching the association from a long term benefit perspective.”

Marketing Thru Marijuana: Differentiate or Die

This is the year that hippie cannabis dies. Woodstock is 50, and has just licensed its name to mega-retailer MedMen.  Hemp is newly de-scheduled and igniting the imaginations of farmers and investors excited about the global opportunity.  Pot Culture has become Pop Culture as legalization has spread coast-to-coast and pushed marijuana into the mainstream.

For grassroots marketers who have been playing in our fragmented American marketplace — where no two states share identical regulations or standards — things have gotten tough in the last year as legal competition from Big Pharma, Big Alcohol, Big Tobacco, Big Consumer Package Goods and Big Agriculture have transformed the playing field.

“As our nascent industry rockets from grassroots to global, it’s Differentiate or Die time for independent companies hoping to stay relevant in an increasingly noisy landscape.” MJBA Founder and veteran marketer David Rheins told MJNews Network.

“You must be able to stand out from the cacophony.  My advice for the licensed cannabis business and ancillary provider alike, is to focus on defining your brand differentiation.  Find a niche, fill a niche.  Your competition moving forward is Big Industry, which has the money, the technology and the wherewithal to take a product from field or factory to shelf better than the little guy ever will.”

His advice: Build your brand authority.  “Big Industry doesn’t understand emerging markets — who the consumer are, their buying preferences and psychographics,” Rheins said.  “As a small business, you are part of the community. You are making a market — defining the industry and your space in it.  No one understands its needs and attitudes of the new market better than the grassroots marketer.  Build your brand around your values, and the values of your customers and your community.   Establish brand loyalty and authority — with your vendors, and your customers, wether you are b2b or b2c — by lending value.”

Differentiate Or Die

Rheins suggests that the New Year is a good time for all marketers to do a brand review.  As an exercise, he encourages his clients to ask their investors, employees, vendors and customers to answer a couple of questions:

1) Describe our brand value  — what do we stand for — in one sentence.

2) What products/services do we offer.

3) What is our unique selling proposition (USP) — what do we do better than other brands?

“You’d be surprised how much intelligence you’ll gain just by analyzing these questions,” Rheins said.  “It only goes to reinforce that today marketing is not simply an exercise of spending money on paid advertising.  Advertising — particularly targeted placements — can be effective, but savvy marketers today depend on an integrated strategy that includes owned media (your company websites and newsletters) and earned media — social media engagement on public platforms with business communities and groups on Facebook, Twitter, Instagram, Reddit.

In this dynamic environment, Rheins advises businesses to stay engaged and stay fresh.

Take An Annual Brand Checkup

1) Do A Brand Review: How well do your customers understand your Brand Values and USP? How well do you understand your customer segments?

2) Website Audit: How fresh is your content? Are you SEO optimized? Are you using your website to gather customer feedback?

3) Social Media Audit: How visible is your brand on key social media platforms?  How often do you post content?  How quickly do you respond to queries or brand mentions? Who in your company is responsible for social media?

4) Community Check Up: How engaged is your brand in your community — not just your cannabis community but your local community?  Do you sponsor local events? Do you give to local charities? How well liked is your brand on Main Street?